SAN DIEGO--(BUSINESS WIRE)--Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) today announced that researchers from the Department of Medicine, University of California San Diego (UCSD), presented preclinical data demonstrating that the Company’s oral drug candidate TRIOLEX™ (HE3286) exhibited anti-diabetic, anti-inflammatory and cholesterol lowering properties in Zucker Diabetic Fatty (ZDF) rats, a commonly used preclinical model of diabetes. TRIOLEX is a proprietary pharmaceutical drug candidate derived from a naturally occurring hormone. The findings were presented by UCSD researchers Min Lu, Ph.D., David A. Patsouris, Ph.D., and Jerrold M. Olefsky, M.D., at the Type 2 Diabetes and Insulin Resistance Keystone Symposia Meeting held January 21st through January 25th, in Banff, Alberta.
